Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 20
Filter
1.
Radiology ; 279(1): 158-66, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26505922

ABSTRACT

PURPOSE: To investigate whether volumetrically derived apparent diffusion coefficient (ADC) from pretreatment diffusion-weighted (DW) magnetic resonance (MR) imaging is associated with disease recurrence in women with locally advanced cervical cancer treated with chemotherapy and radiation therapy. MATERIALS AND METHODS: An ethics board-approved, retrospective study was conducted in 85 women with stage IB-IVA cervical cancer treated with chemo- and radiation therapy in 2009-2013. All patients underwent MR imaging for staging, including T2-weighted and DW MR imaging series, by using a 1.5- or 3.0-T imager. The mean, median, 75th, 90th, and 95th percentile ADCs (ADCmean, ADC50, ADC75, ADC90, and ADC95, respectively) of all voxels that comprised each tumor were extracted and normalized to the mean urine ADC (nADCmean, nADC50, nADC75, nADC90, and nADC95, respectively) to reduce variability. The primary outcome was disease-free survival (DFS). Uni- and multivariable Cox regression analyses were used to evaluate the association of ADC parameters and relevant clinical variables with DFS. RESULTS: Of the 85 women included, 62 were free of disease at last follow-up. Median follow-up was 37 months (range, 5-68 months). Significant variables at univariable analysis included T2-weighted derived tumor diameter, para-aortic nodal involvement, advanced stage, ADC90 and ADC95, nADC75, nADC90, and nADC95. Normalized parameters were more highly associated (hazard ratio per 0.01 increase in normalized ADC, 0.91-0.94; P < .04). Because nADC75, nADC90, and nADC95 were highly correlated, only nADC95 (which had the lowest P value) was included in multivariable analysis. At multivariable analysis, absolute and normalized ADC95 remained associated with DFS (hazard ratio, 0.90-0.98; P < .05). CONCLUSION: The volumetric ADC95 may be a useful imaging metric to predict treatment failure in patients with locally advanced cervical cancer treated with chemo- and radiation therapy.


Subject(s)
Diffusion Magnetic Resonance Imaging/methods , Neoplasm Recurrence, Local/diagnosis , Uterine Cervical Neoplasms/pathology , Combined Modality Therapy , Female , Humans , Magnetic Resonance Imaging, Interventional , Middle Aged , Neoplasm Staging , Retrospective Studies , Survival Rate , Treatment Outcome , Uterine Cervical Neoplasms/drug therapy , Uterine Cervical Neoplasms/radiotherapy
2.
N Engl J Med ; 373(4): 307-16, 2015 Jul 23.
Article in English | MEDLINE | ID: mdl-26200977

ABSTRACT

BACKGROUND: Most women with breast cancer who undergo breast-conserving surgery receive whole-breast irradiation. We examined whether the addition of regional nodal irradiation to whole-breast irradiation improved outcomes. METHODS: We randomly assigned women with node-positive or high-risk node-negative breast cancer who were treated with breast-conserving surgery and adjuvant systemic therapy to undergo either whole-breast irradiation plus regional nodal irradiation (including internal mammary, supraclavicular, and axillary lymph nodes) (nodal-irradiation group) or whole-breast irradiation alone (control group). The primary outcome was overall survival. Secondary outcomes were disease-free survival, isolated locoregional disease-free survival, and distant disease-free survival. RESULTS: Between March 2000 and February 2007, a total of 1832 women were assigned to the nodal-irradiation group or the control group (916 women in each group). The median follow-up was 9.5 years. At the 10-year follow-up, there was no significant between-group difference in survival, with a rate of 82.8% in the nodal-irradiation group and 81.8% in the control group (hazard ratio, 0.91; 95% confidence interval [CI], 0.72 to 1.13; P=0.38). The rates of disease-free survival were 82.0% in the nodal-irradiation group and 77.0% in the control group (hazard ratio, 0.76; 95% CI, 0.61 to 0.94; P=0.01). Patients in the nodal-irradiation group had higher rates of grade 2 or greater acute pneumonitis (1.2% vs. 0.2%, P=0.01) and lymphedema (8.4% vs. 4.5%, P=0.001). CONCLUSIONS: Among women with node-positive or high-risk node-negative breast cancer, the addition of regional nodal irradiation to whole-breast irradiation did not improve overall survival but reduced the rate of breast-cancer recurrence. (Funded by the Canadian Cancer Society Research Institute and others; MA.20 ClinicalTrials.gov number, NCT00005957.).


Subject(s)
Breast Neoplasms/radiotherapy , Lymphatic Metastasis/radiotherapy , Adult , Aged , Aged, 80 and over , Antineoplastic Agents/therapeutic use , Breast Neoplasms/mortality , Breast Neoplasms/therapy , Combined Modality Therapy , Female , Follow-Up Studies , Humans , Mastectomy, Segmental , Middle Aged , Neoplasm Recurrence, Local/prevention & control , Neoplasm Staging , Radiation Dosage , Radiotherapy/adverse effects , Risk , Sentinel Lymph Node Biopsy , Survival Analysis
3.
Radiother Oncol ; 114(1): 17-21, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25483219

ABSTRACT

BACKGROUND AND PURPOSE: This study describes the process and outcomes of breast radiotherapy (RT) quality assurance (QA) rounds, seeking to identify variables associated with plan modifications. MATERIALS AND METHODS: Real-time data were prospectively collected over 2 years. Descriptive statistics determined the proportion of cases requiring no (A), minor (B), or major (C) modifications, which were then subjected to univariate and multivariate analyses. RESULTS: A total of 2223 breast cancer QA cases were reviewed; 47 cases (2.1%) underwent a minor, and 52 cases (2.3%) required a major modification. Common changes included boost, volume, seroma, and bolus. On univariate analysis, regional nodal irradiation (RNI), tumour size, and axillary node dissection were significantly associated with major modifications. Upon multivariate analysis, the only independent predictor was RNI (OR 2.12, p=0.0075). For patients with no RNI, <2 cm tumours, no axillary lymph node dissection, and no boosts (n=420); the likelihood of category C was only 1.4%. CONCLUSIONS: It is feasible to conduct QA review for all breast cancer cases prior to commencing RT. Patients undergoing RNI had a higher likelihood of plan modifications; a group with low risk of modification was identified, which could direct future re-structuring of QA rounds.


Subject(s)
Breast Neoplasms/radiotherapy , Adult , Breast Neoplasms/surgery , Cancer Care Facilities/organization & administration , Cancer Care Facilities/standards , Feasibility Studies , Female , Humans , Lymph Node Excision/methods , Middle Aged , Patient Care Planning/organization & administration , Patient Care Planning/standards , Prospective Studies , Quality Assurance, Health Care
4.
J Clin Oncol ; 31(30): 3758-63, 2013 Oct 20.
Article in English | MEDLINE | ID: mdl-24043733

ABSTRACT

PURPOSE: Because of its morbidity and chronicity, arm lymphedema remains a concerning complication of breast cancer treatment. Although massage-based decongestive therapy is often recommended, randomized trials have not consistently demonstrated benefit over more conservative measures. PATIENTS AND METHODS: Women previously treated for breast cancer with lymphedema were enrolled from six institutions. Volumes were calculated from circumference measurements. Patients with a minimum of 10% volume difference between their arms were randomly assigned to either compression garments (control) or daily manual lymphatic drainage and bandaging followed by compression garments (experimental). The primary outcome was percent reduction in excess arm volume from baseline to 6 weeks. RESULTS: A total of 103 women were randomly assigned, and 95 were evaluable. Mean reduction of excess arm volume was 29.0% in the experimental group and 22.6% in the control group (difference, 6.4%; 95% CI, -6.8% to 20.5%; P = .34). Absolute volume loss was 250 mL and 143 mL in the experimental and control groups, respectively (difference, 107 mL; 95% CI, 13 to 203 mL; P = .03). There was no difference between groups in the proportion of patients losing 50% or greater excess arm volume. Quality of life (Short Form-36 Health Survey) and arm function were not different between groups. CONCLUSION: This trial was unable to demonstrate a significant improvement in lymphedema with decongestive therapy compared with a more conservative approach. The failure to detect a difference may have been a result of the relatively small size of our trial.


Subject(s)
Breast Neoplasms/therapy , Clothing , Compression Bandages , Lymphedema/etiology , Lymphedema/therapy , Massage , Upper Extremity , Adult , Aged , Breast Neoplasms/complications , Confounding Factors, Epidemiologic , Drainage , Female , Humans , Middle Aged , Quality of Life , Treatment Outcome
5.
Radiat Oncol ; 8: 128, 2013 May 24.
Article in English | MEDLINE | ID: mdl-23705661

ABSTRACT

BACKGROUND: To examine the role of radiotherapy (RT) in uterine leiomyosarcomas (LMS) and to determine the patient population who may benefit from RT. METHODS: From 1998-2008, 69 patients with primary uterine LMS underwent hysterectomy with or without pelvic radiotherapy to a median dose of 45 Gy. Univariate analysis was performed using the Kaplan-Meier method and cumulative-incidence function, and multivariate analyses using Fine and Gray or Cox proportional hazard models. RESULTS: Following surgery, 32 out of 69 patients received RT. There was no evidence of any correlation between patient, disease and treatment characteristics and the use of RT. Median follow-up was 57 months. RT was associated with reduced local recurrence (3y LR 19% vs. 39%; Gray's p = 0.019) and improved overall survival (3y OS 69% vs. 35%; log-rank p = 0.025) on univariate analysis. Multivariate analysis demonstrated that RT reduced LR (HR: 0.28, CI: 0.11-0.69, p = 0.006) and increased OS (HR: 0.44, CI: 0.23-0.85, p = 0.014) independent of other clinical and pathologic factors. Positive surgical margins increased the odds of LR (HR: 5.6, CI: 2.3-13.4, p = 0.00012). Large tumor size and advanced stage (II-IV) were associated with the development of distant metastases and inferior OS. CONCLUSIONS: Postoperative pelvic RT reduces LR and improves OS of patients with uterine LMS.


Subject(s)
Leiomyosarcoma/radiotherapy , Uterine Neoplasms/radiotherapy , Female , Humans , Kaplan-Meier Estimate , Leiomyosarcoma/mortality , Leiomyosarcoma/surgery , Middle Aged , Radiotherapy, Adjuvant , Uterine Neoplasms/mortality , Uterine Neoplasms/surgery
6.
Pract Radiat Oncol ; 2(2): 114-21, 2012.
Article in English | MEDLINE | ID: mdl-24674087

ABSTRACT

PURPOSE: Breast cancer is managed by a multidisciplinary team with a goal for the timely provision of high quality care. Given radiation oncologist (RO) time constraints, an opportunity arises for task delegation of breast seroma target delineation to an advanced practice clinical specialist radiation therapist (CSRT) with clinical and technical expertise to facilitate treatment planning. To explore this further, we quantitatively evaluated the variability in post-surgical seroma delineation between the CSRT and ROs. METHODS: Specialized site specific training was provided to the CSRT, who, with 7 ROs, independently contoured the seroma and graded its clarity, using the cavity visualization score (CVS), for 20 patients with clinical stage Tis-2N0 breast tumors. The conformity indices were analyzed for all possible pairs of delineations. The estimated "true" seroma contour was derived from the RO contours using the simultaneous truth and performance level estimation algorithm. Generalized kappa coefficient and center of mass metrics were used to examine the performance level of the CSRT in seroma delineations. RESULTS: The CVS of the CSRT correlated well with the mean RO-group CVS, (Spearman ρ = 0.87, P < .05). The mean seroma conformity index for the RO group was 0.61 and 0.65 for the CSRT; a strong correlation was observed between the RO and CSRT conformity indices (Spearman ρ = 0.95, P < .05). Almost perfect agreement levels were observed between the CSRT contours and the STAPLE RO consensus contours, with an overall kappa statistic of 0.81 (P < .0001). The average center of mass shift between the CSRT and RO consensus contour was 1.69 ± 1.13 mm. CONCLUSIONS: Following specialized education and training, the CSRT delineated seroma targets clinically comparable with those of the radiation oncologists in women with early breast tumors suitable for accelerated partial breast or whole breast radiotherapy following lumpectomy. This study provides support for potential task delegation of breast seroma delineation to the CSRT in our current multidisciplinary environment. Further study is needed to assess the impact of this role expansion on radiotherapy system efficiency.

7.
Int J Radiat Oncol Biol Phys ; 74(4): 1157-64, 2009 Jul 15.
Article in English | MEDLINE | ID: mdl-19101097

ABSTRACT

PURPOSE: To determine the feasibility and benefits of optimized magnetic resonance imaging (MRI)-guided brachytherapy (BT) for cancer of the cervix. METHODS AND MATERIALS: A total of 20 patients with International Federation of Gynecology and Obstetrics Stage IB-IV cervical cancer had an MRI-compatible intrauterine BT applicator inserted after external beam radiotherapy. MRI scans were acquired, and the gross tumor volume at diagnosis and at BT, the high-risk (HR) and intermediate-risk clinical target volume (CTV), and rectal, sigmoid, and bladder walls were delineated. Pulsed-dose-rate BT was planned and delivered in a conventional manner. Optimized MRI-based plans were developed and compared with the conventional plans. RESULTS: The HR CTV and intermediate-risk CTV were adequately treated (the percentage of volume treated to >or=100% of the intended dose was >95%) in 70% and 85% of the patients with the conventional plans, respectively, and in 75% and 95% of the patients with the optimized plans, respectively. The minimal dose to the contiguous 2 cm(3) of the rectal, sigmoid, and bladder wall volume was 16 +/- 6.2, 25 +/- 8.7, and 31 +/- 9.2 Gy, respectively. With MRI-guided BT optimization, it was possible to maintain coverage of the HR-CTV and reduce the dose to the normal tissues, especially in patients with small tumors at BT. In these patients, the HR percentage of volume treated to >or=100% of the intended dose approached 100% in all cases, and the minimal dose to the contiguous 2-cm(3) of the rectum, sigmoid, and bladder was 12-32% less than with conventional BT planning. CONCLUSION: MRI-based BT for cervical cancer has the potential to optimize primary tumor dosimetry and reduce the dose to critical normal tissues, particularly in patients with small tumors.


Subject(s)
Brachytherapy/methods , Magnetic Resonance Imaging, Interventional , Uterine Cervical Neoplasms/radiotherapy , Adenocarcinoma, Clear Cell/pathology , Adenocarcinoma, Clear Cell/radiotherapy , Adult , Aged , Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/radiotherapy , Colon, Sigmoid/anatomy & histology , Feasibility Studies , Female , Humans , Middle Aged , Radiation Injuries/prevention & control , Radiotherapy Dosage , Rectum/anatomy & histology , Tumor Burden , Urinary Bladder/anatomy & histology , Uterine Cervical Neoplasms/pathology
8.
Int J Radiat Oncol Biol Phys ; 70(5): 1507-15, 2008 Apr 01.
Article in English | MEDLINE | ID: mdl-18164850

ABSTRACT

PURPOSE: Internal tumor and organ movement is important when considering intensity-modulated radiotherapy for patients with cancer of the cervix because of the tight margins and steep dose gradients. In this study, the internal movement of the tumor, cervix, and uterus were examined using serial cinematic magnetic resonance imaging scans and point-of-interest analysis. METHODS AND MATERIALS: Twenty patients with Stage IB-IVA cervical cancer underwent pelvic magnetic resonance imaging before treatment and then weekly during external beam radiotherapy. In each 30-min session, sequential T(2)-sagittal magnetic resonance imaging scans were obtained. The points of interest (cervical os, uterine canal, and uterine fundus) were traced on each image frame, allowing the craniocaudal and anteroposterior displacements to be measured. The mean displacements and trends were analyzed using mixed linear models. Prediction intervals were calculated to determine the internal target margins. RESULTS: Large interscan motion was found for all three points of interest that was only partially explained by the variations in bladder and rectal filling. The intrascan motion was much smaller. Both inter- and intrascan motion was greatest at the fundus of the uterus, less along the canal, and least at the cervical os. The isotropic internal target margins required to encompass 90% of the interscan motion were 4 cm at the fundus and 1.5 cm at the os. In contrast, smaller margins of 1 cm and 0.45 cm, respectively, were adequate to encompass the intrascan motion alone. CONCLUSION: Daily soft-tissue imaging with correction for interfractional motion or adaptive replanning will be important if the benefits of intensity-modulated radiotherapy are to be maximized in women with cervical cancer.


Subject(s)
Magnetic Resonance Imaging, Cine/methods , Movement , Radiotherapy, Intensity-Modulated , Uterine Cervical Neoplasms/radiotherapy , Uterus , Adult , Aged , Cervix Uteri , Female , Humans , Linear Models , Middle Aged , Reproducibility of Results , Uterine Cervical Neoplasms/pathology
9.
Int J Radiat Oncol Biol Phys ; 70(1): 126-33, 2008 Jan 01.
Article in English | MEDLINE | ID: mdl-17768016

ABSTRACT

PURPOSE: To measure regression of cancer of the uterine cervix during external beam radiotherapy using magnetic resonance imaging, derive radiobiologic parameters from a mathematical model of tumor regression, and compare these parameters with the pretreatment measurements of tumor hypoxia. METHODS AND MATERIALS: A total of 27 eligible patients undergoing external beam radiotherapy for cervical cancer underwent weekly magnetic resonance imaging scans. The tumor volume was assessed on each of these scans and the rate of regression plotted. A radiobiologic model was formulated to simulate the effect on tumor regression of the surviving proportion of cells after 2 Gy (SP(2)), the cell clearance constant (clearance of irreparably damaged cells from the tumor [T(c)]), and accelerated repopulation. Nonlinear regression analysis was used to fit the radiobiologic model to the magnetic resonance imaging-derived tumor volumes and to derive the estimates of SP(2) and T(c) for each patient. These were compared to the pretreatment hypoxia measurements. RESULTS: The initial tumor volume was 8-209 cm(3). The relative reduction in volume during treatment was 0.02-0.79. The simulations using representative values of the independent biologic variables derived from published data showed SP(2) and T(c) to strongly influence the shape of the volume-response curves. Nonlinear regression analysis yielded a median SP(2) of 0.71 and median T(c) of 10 days. Tumors with a high SP(2) >0.71 were significantly more hypoxic at diagnosis (p = 0.02). CONCLUSION: The results of our study have shown that cervical cancer regresses during external beam radiotherapy, although marked variability is present among patients and is influenced by underlying biologic processes, including cellular sensitivity to radiotherapy and proliferation. Better understanding of the biologic mechanisms might facilitate novel adaptive treatment strategies in future studies.


Subject(s)
Cell Hypoxia , Magnetic Resonance Imaging , Models, Biological , Tumor Burden/radiation effects , Uterine Cervical Neoplasms/radiotherapy , Adenocarcinoma/pathology , Adenocarcinoma/physiopathology , Adenocarcinoma/radiotherapy , Adult , Aged , Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/physiopathology , Carcinoma, Squamous Cell/radiotherapy , Cell Survival , Dose Fractionation, Radiation , Female , Follow-Up Studies , Humans , Middle Aged , Radiation Tolerance/physiology , Radiobiology , Regression Analysis , Relative Biological Effectiveness , Remission Induction/methods , Uterine Cervical Neoplasms/pathology , Uterine Cervical Neoplasms/physiopathology
10.
Int J Radiat Oncol Biol Phys ; 67(1): 97-103, 2007 Jan 01.
Article in English | MEDLINE | ID: mdl-17056201

ABSTRACT

PURPOSE: To evaluate the toxicity and effectiveness of celecoxib in combination with definitive chemoradiotherapy (CRT) in women with locally advanced cervical cancer. METHODS AND MATERIALS: Thirty-one patients were accrued to a phase I-II trial of celecoxib 400 mg by mouth twice per day for 2 weeks before and during CRT. Tumor oxygenation (HP(5)) and interstitial fluid pressure (IFP) were measured before and 2 weeks after celecoxib administration alone. The median follow-up time was 2.7 years (range, 1.1-4.4 years). RESULTS: The most common acute G3/4 toxicities were hematologic (4/31, 12.9%) and gastrointestinal (5/31, 16.1%) largely attributed to chemotherapy. Late G3/4 toxicity was seen in 4 of 31 patients (13.7% actuarial risk at 2 yr), including fistulas in 3 patients (9.7%). Within the first year of follow-up, 25 of 31 patients (81%) achieved complete response (CR), of whom 20 remained in CR at last follow-up. After 2 weeks of celecoxib administration before CRT, the median IFP decreased slightly (median absolute, -4.6 mm Hg; p = 0.09; relative, -21%; p = 0.07), whereas HP(5) did not change significantly (absolute increase, 3.6%; p = 0.51; median relative increase, 11%; p = 0.27). No significant associations were seen between changes in HP(5) or IFP and response to treatment (p = 0.2, relative HP(5) change and p = 0.14, relative IFP change). CONCLUSIONS: Celecoxib in combination with definitive CRT is associated with acceptable acute toxicity, but higher than expected late complications. Celecoxib is associated with a modest reduction in the angiogenic biomarker IFP, but this does not correspond with tumor response.


Subject(s)
Cyclooxygenase 2 Inhibitors/adverse effects , Extracellular Fluid/physiology , Pyrazoles/adverse effects , Sulfonamides/adverse effects , Uterine Cervical Neoplasms/drug therapy , Uterine Cervical Neoplasms/radiotherapy , Adult , Aged , Biomarkers, Tumor , Celecoxib , Cell Hypoxia/drug effects , Combined Modality Therapy/methods , Cyclooxygenase 2 Inhibitors/therapeutic use , Double-Blind Method , Female , Follow-Up Studies , Gastrointestinal Diseases/chemically induced , Humans , Leukopenia/chemically induced , Middle Aged , Oxygen Consumption , Prospective Studies , Pyrazoles/therapeutic use , Rectovaginal Fistula/chemically induced , Remission Induction , Sulfonamides/therapeutic use , Uterine Cervical Neoplasms/metabolism , Uterine Cervical Neoplasms/mortality
11.
Radiother Oncol ; 80(2): 132-7, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16920212

ABSTRACT

OBJECTIVES: Hypoxia and high interstitial fluid pressure (IFP) have been shown to independently predict for nodal and distant metastases, as well as survival, in patients with cervix cancer. Using data from our prospective trial, we updated a cohort of patients treated with definitive radiation alone without chemotherapy, to assess the long-term prognostic impact of these microenvironmental features. METHODS: Between April 1994 and January 1999, 107 eligible patients with cervix cancer were entered into a prospective study of tumor oxygenation and IFP prior to primary radiation therapy. Oxygenation data are presented as the hypoxic proportion, defined as the percentage of pO(2) readings <5 mm Hg (abbreviated as HP(5)). Patients with HP(5) values >50% were considered to have hypoxic tumors. IFP is presented in mmHg, divided into high and low IFP groups by the median value. Patients ranged in age from 23 to 78 years with a mean of 53 years. The maximum tumor size ranged from 2 to 10 cm, with a median diameter of 5 cm. FIGO stage was IB in 28 patients, IIA in 4, IIB in 42 and IIIB in 33 patients. Twenty-two patients (21%) had evidence of pelvic lymph node involvement on staging CT abdomen/pelvis or MR pelvis. HP(5) ranged from 0% to 99% with a median of 48%. IFP ranged from -3 to 48 mm Hg (median 19 mm Hg). Median follow-up was 6.7 years (range 0.9-10.6). RESULTS: Disease-free survival (DFS) at 5 years was 50%. Five year DFS was 42% for patients with hypoxic tumors (HP(5)>50%), and 58% in patients with oxygenated tumors (HR 1.01 per %, p=0.05). DFS at 5 years was 42% for patients with interstitial hypertension (IFP >19 mm Hg), and 63% in patients with IFP

Subject(s)
Extracellular Fluid/physiology , Oxygen/metabolism , Uterine Cervical Neoplasms/metabolism , Uterine Cervical Neoplasms/radiotherapy , Adult , Aged , Cell Hypoxia/physiology , Female , Humans , Hydrostatic Pressure , Middle Aged , Prognosis , Prospective Studies , Uterine Cervical Neoplasms/pathology
12.
Int J Radiat Oncol Biol Phys ; 63(4): 1077-82, 2005 Nov 15.
Article in English | MEDLINE | ID: mdl-16024181

ABSTRACT

PURPOSE: To compare survival and severe late radiation toxicity between patients who received continuous low-dose-rate (LDR) brachytherapy (BT) and pulsed-dose-rate (PDR) BT for cervical cancer. METHODS AND MATERIALS: A retrospective review of cervical cancer patients who underwent primary radiotherapy with or without concurrent cisplatin was performed. Late Grade 3 or worse toxicities were assessed using the National Cancer Institute Common Toxicity Criteria. The study endpoints were overall and disease-free survival and the probability of severe late toxicity. RESULTS: A total of 109 patients (65.7%) received LDR BT and 57 (34.3%) received PDR BT. Seventy patients received concurrent chemotherapy with cisplatin. The 3-year overall survival and disease-free survival rate was 70% and 57% for the LDR group and 82% and 70% for the PDR group, respectively (p = 0.25 and p = 0.19). The 3-year probability rate for late Grade 3 or worse toxicity was 7.4% for LDR BT patients and 7.6% for PDR BT patients, respectively (p = 0.69) and 6.9% and 7.6%, respectively, for concurrent chemotherapy vs. none (p = 0.69). CONCLUSION: No difference was found in severe late toxicity, overall survival, or disease-free survival between the LDR and PDR groups.


Subject(s)
Brachytherapy/adverse effects , Uterine Cervical Neoplasms/radiotherapy , Adult , Aged , Aged, 80 and over , Brachytherapy/methods , Female , Humans , Middle Aged , Radiation Injuries/pathology , Retrospective Studies , Survival Analysis , Uterine Cervical Neoplasms/mortality
13.
Int J Radiat Oncol Biol Phys ; 62(1): 104-10, 2005 May 01.
Article in English | MEDLINE | ID: mdl-15850909

ABSTRACT

PURPOSE: To assess the feasibility and morbidity of sequential cytoreductive surgery, carboplatin/paclitaxel chemotherapy, and consolidative abdominopelvic radiotherapy (APRT) in ovarian cancer. METHODS AND MATERIALS: Between 1998 and 2000, 29 patients with optimally cytoreduced epithelial ovarian cancer were treated with carboplatin (135 mg/m2) and paclitaxel (area under the curve [AUC] of 6) followed by APRT in a prospective protocol. All patients were clinically, radiographically, and biochemically (CA-125) free of disease at the completion of chemotherapy. Abdominopelvic radiotherapy was delivered using 6 MV anterior-posterior photon fields to encompass the peritoneal cavity. Median follow-up was 4 years. RESULTS: Two patients experienced Radiation Therapy Oncology Group Grade 3 gastrointestinal toxicity during APRT; 6 patients, Grade 3 or 4 neutropenia; and 3 patients, Grade 3 or 4 thrombocytopenia. Overall, 10 patients had Grade 3 or 4 acute toxicity. All of the acute side effects resolved after treatment was completed, and there were no serious consequences such as sepsis or hemorrhage. Abdominopelvic radiotherapy was abandoned prematurely in 3 patients. Late side effects were seen in 5 patients, including 1 small bowel obstruction, 2 symptomatic sacral insufficiency fractures, 1 case of severe dyspareunia, and 1 case of prolonged fatigue. All resolved with supportive management. The 4-year actuarial disease-free survival was 57%, and the overall survival was 92%. Eleven of 12 patients who relapsed received salvage chemotherapy, which was well tolerated. CONCLUSIONS: Abdominopelvic radiotherapy after optimal surgery and carboplatin/paclitaxel chemotherapy is associated with an acceptable risk of acute and late side effects and does not limit subsequent salvage chemotherapy. Consolidative APRT warrants further investigation as a means of improving the outcome of patients with ovarian cancer.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Ovarian Neoplasms/drug therapy , Ovarian Neoplasms/radiotherapy , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Carboplatin/administration & dosage , Combined Modality Therapy , Disease-Free Survival , Feasibility Studies , Female , Humans , Middle Aged , Ovarian Neoplasms/surgery , Paclitaxel/administration & dosage , Prospective Studies , Radiotherapy/adverse effects , Radiotherapy/methods , Treatment Outcome
14.
Discov Med ; 5(25): 55-7, 2005 Feb.
Article in English | MEDLINE | ID: mdl-20704924

ABSTRACT

Extract: Women who present with early breast cancer are initially treated with surgical lumpectomy (removal of the tumor mass) followed by radiation therapy. Breast radiation therapy is well established as the "standard of care" for women with early breast cancer as it has consistently been shown, in randomized clinical trials, to reduce the risk of a relapse in the breast by 60-75%. Excellent control rates and survival following lumpectomy and post-operative breast radiation demonstrate that mastectomies (removal of the entire breast, including the tumor) are normally not necessary for early disease. This is consistent with the consensus of multiple experts in the field following their assessment of multiple clinical trials comparing lumpectomy and mastectomy. The increasing use of mammographic screening for breast cancer has resulted in earlier diagnosis of the disease when the tumors are smaller and so they have not yet spread to the axillary lymph nodes (under the armpits). It has been recognized that systemic adjuvant treatment with the anti-estrogen medication, tamoxifen, that prevents estrogen from stimulating receptive tumor cells, also reduces breast cancer relapse as well as preventing metastatic spread of the disease and improving survival. Survival, however, does not appear to be affected by radiation treatment, and women who are diagnosed with the disease early and who have negative pathological findings in their axillary lymph nodes have a lower risk of breast cancer relapse overall. This has led researchers to look for low-risk subgroups of these women who might reasonably be able to avoid the side-effects and inconvenience of radiation.

15.
Breast J ; 10(6): 481-6, 2004.
Article in English | MEDLINE | ID: mdl-15569202

ABSTRACT

The goal of this study was to determine the frequency of alternative therapy use in postmenopausal women with early stage breast cancer who were enrolled in a randomized clinical trial designed to determine the value of breast irradiation after treatment with breast-conserving surgery and tamoxifen. A questionnaire was given to 300 patients, ages 52 to 90 years, after completion of radiation therapy (if any). Of the 290 respondents, 78 (27%) had used some form of alternative therapy. Of these, 60.3% started after the diagnosis of breast cancer. Users of alternative therapies were significantly younger than nonusers (67.0 +/- 8.4 years versus 70.0 +/- 8.7 years, p = 0.009) and they used a median of one type of therapy per person (range 1-13). Users of alternative therapies were more likely to have experienced symptoms (stiffness, pain, numbness, or swelling) in the ipsilateral shoulder or arm after treatment of their breast cancers compared to nonusers (odds ratio [OR] = 2.0, p = 0.02). This relationship between alternative therapy use and symptoms was strongest in the group who started alternative therapies after breast cancer diagnosis (OR = 2.1, p = 0.05). On multivariate analysis, younger age and radiotherapy treatment were related to alternative therapy use. In conclusion, 27% of patients with early stage breast cancer used alternative therapy. Users were more likely to be younger and to experience shoulder or arm symptoms after breast-conserving surgery with radiation.


Subject(s)
Breast Neoplasms/therapy , Complementary Therapies/statistics & numerical data , Aged , Aged, 80 and over , Breast Neoplasms/epidemiology , Breast Neoplasms/pathology , Combined Modality Therapy , Estrogen Antagonists/administration & dosage , Female , Humans , Mastectomy , Middle Aged , Ontario/epidemiology , Postmenopause , Prevalence , Radiotherapy, Adjuvant , Randomized Controlled Trials as Topic , Surveys and Questionnaires , Tamoxifen/administration & dosage
16.
N Engl J Med ; 351(10): 963-70, 2004 Sep 02.
Article in English | MEDLINE | ID: mdl-15342804

ABSTRACT

BACKGROUND: We determined the effect of breast irradiation plus tamoxifen on disease-free survival and local relapse in women 50 years of age or older who had T1 or T2 node-negative breast cancer. METHODS: Between December 1992 and June 2000, 769 women with early breast cancer (tumor diameter, 5 cm or less) were randomly assigned to receive breast irradiation plus tamoxifen (386 women) or tamoxifen alone (383 women). The median follow-up was 5.6 years. RESULTS: The rate of local relapse at five years was 7.7 percent in the tamoxifen group and 0.6 percent in the group given tamoxifen plus irradiation (hazard ratio, 8.3; 95 percent confidence interval, 3.3 to 21.2; P<0.001), with corresponding five-year disease-free survival rates of 84 percent and 91 percent (P=0.004). A planned subgroup analysis of 611 women with T1, receptor-positive tumors indicated a benefit from radiotherapy (five-year rates of local relapse, 0.4 percent with tamoxifen plus radiotherapy and 5.9 percent with tamoxifen alone; P<0.001). Overall, there was a significant difference in the rate of axillary relapse at five years (2.5 percent in the tamoxifen group and 0.5 percent in the group given tamoxifen plus irradiation, P=0.049), but no significant difference in the rates of distant relapse or overall survival. CONCLUSIONS: As compared with tamoxifen alone, radiotherapy plus tamoxifen significantly reduces the risk of breast and axillary recurrence after lumpectomy in women with small, node-negative, hormone-receptor-positive breast cancers.


Subject(s)
Antineoplastic Agents, Hormonal/therapeutic use , Breast Neoplasms/drug therapy , Breast Neoplasms/radiotherapy , Mastectomy, Segmental , Tamoxifen/therapeutic use , Aged , Analysis of Variance , Antineoplastic Agents, Hormonal/adverse effects , Breast Neoplasms/surgery , Combined Modality Therapy , Disease-Free Survival , Female , Follow-Up Studies , Humans , Lymphatic Metastasis , Middle Aged , Neoplasm Recurrence, Local/epidemiology , Neoplasm Recurrence, Local/prevention & control , Neoplasm Staging , Neoplasms, Hormone-Dependent/drug therapy , Neoplasms, Hormone-Dependent/radiotherapy , Neoplasms, Hormone-Dependent/surgery , Prognosis , Radiotherapy/adverse effects , Risk Factors , Survival Rate , Tamoxifen/adverse effects
17.
J Contin Educ Health Prof ; 24(2): 76-81, 2004.
Article in English | MEDLINE | ID: mdl-15279132

ABSTRACT

INTRODUCTION: Severe acute respiratory syndrome (SARS) struck Toronto in the spring of 2003, causing many deaths, serious morbidity, forced quarantine of thousands of individuals, and the closure of all provincial hospitals for several weeks. Given the direction by public health authorities to cancel or postpone all continuing medical education (CME) courses, including those sponsored by the University of Toronto Faculty of Medicine, SARS has had a profound effect on the delivery of CME in Toronto and beyond. METHOD: Case study design using existing documents and self-report. RESULTS: The immediate, specific response of the University of Toronto CME program to SARS is described for the period from March 2003 to September 2003. DISCUSSION: During major outbreaks of infectious disease, continuing education providers should maintain regular contact with public health authorities and learners, enact a rational process for postponing or canceling courses, and implement a disaster plan flexible enough to ensure the deliver, of education using technological advances.


Subject(s)
Education, Medical, Continuing/organization & administration , Severe Acute Respiratory Syndrome/therapy , Humans , Ontario/epidemiology , Organizational Case Studies , Public Health Practice , Severe Acute Respiratory Syndrome/epidemiology
18.
Clin Cancer Res ; 9(12): 4387-95, 2003 Oct 01.
Article in English | MEDLINE | ID: mdl-14555510

ABSTRACT

PURPOSE: To examine the prognostic value of tumor proliferation measurements in women with carcinoma of the uterine cervix. We report an update of a prospective study focusing on whether pretreatment proliferation parameters are associated with clinical outcome, relative to other established clinical factors. MATERIALS AND METHODS: One hundred and one patients were recruited into the study from years 1991 to 1999. The LI for in vivo bromodeoxyuridine incorporation by the tumor and the potential doubling time (T(pot)) were determined by flow cytometry (fc). LI and its staining pattern were also assessed by immunohistochemistry (ih) using tissue sections. Apoptosis was assessed histologically using morphological criteria. Patients were treated with definitive radiation therapy. RESULTS: A successful fc measurement for LI-fc and T(pot) was possible in 95 patients (94%). The median/mean LI-fc was 6.6/7.6% (range 1.4-36.1%), and for LI-ih, 10.8/11.5%. To date, 43 patients have died of disease, and the median follow-up for alive patients is 6.2 years (range 1.3-9.3 years). Among 88 patients who completely responded to treatment, 40 patients have relapsed (14 pelvic, 23 distant, and 3 pelvic and distant). In univariate analysis, the significant factors for adverse disease-free survival were large tumor size (P = 0.0001), low hemoglobin (P = 0.001), pelvic lymph node status (P = 0.004), stage (P = 0.013), and overall treatment time (P = 0.0008). In multivariate analysis, only tumor size, pelvic lymph node status, and overall treatment time remained significant for disease-free survival. LI-fc, LI-ih, T(pot), ploidy, pattern of bromodeoxyuridine staining, and apoptosis were not significantly associated with clinical outcome in univariate or multivariate analyses. CONCLUSIONS: These mature data indicate that none of the pretreatment proliferation parameters have prognostic significance in the radical radiotherapy of carcinoma of the uterine cervix, despite the significance of overall treatment time for treatment outcome.


Subject(s)
Uterine Cervical Neoplasms/pathology , Uterine Cervical Neoplasms/radiotherapy , Adenocarcinoma/pathology , Adenocarcinoma/radiotherapy , Adenocarcinoma/secondary , Adult , Aged , Aged, 80 and over , Apoptosis , Bromodeoxyuridine , Carcinoma, Adenosquamous/pathology , Carcinoma, Adenosquamous/radiotherapy , Carcinoma, Adenosquamous/secondary , Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/radiotherapy , Carcinoma, Squamous Cell/secondary , Cell Division , Disease-Free Survival , Female , Flow Cytometry , Humans , Immunoenzyme Techniques , Lymphatic Metastasis , Middle Aged , Neoplasm Staging , Prospective Studies , Radiation-Sensitizing Agents , Survival Rate , Treatment Outcome
19.
Cancer ; 97(6): 1369-75, 2003 Mar 15.
Article in English | MEDLINE | ID: mdl-12627499

ABSTRACT

BACKGROUND: The purpose of the current study was to identify the factors that contribute to postoperative arm symptoms following breast conserving surgery in a well-defined cohort of node negative breast carcinoma patients. METHODS: A convenience sample of 370 women >/= 50 years of age with node negative breast carcinoma who were participants in a randomized controlled trial designed to assess the need for breast radiation in addition to tamoxifen were surveyed. Axillary dissection was optional for patients 65 years or older and who were clinically node negative. RESULTS: A total of 65.1% (241/370) of women had ipsilateral shoulder or arm symptoms. Multivariate analysis revealed that axillary dissection, breast radiation, and younger age (odds ratio = 11.2, 1.65, and 3.8 respectively) were significantly (P < 0.05) associated with increased ipsilateral shoulder or arm symptoms. Treatment with axillary dissection and breast radiation were significant factors (P < 0.02) associated with the self-reporting of arm swelling (odds ratio = 4.4 and 2.0, respectively). Patients 70 years old or greater reported significantly fewer arm symptoms (odds ratio = 0.26, P < 0.05) after axillary dissection. CONCLUSIONS: Arm symptoms were present in about 80% of patients who underwent breast conserving surgery, axillary dissection, and breast radiation in the current study. These symptoms were significantly associated with the use of axillary dissection, breast radiation, and younger age. Older patients experienced fewer arm symptoms after standard treatment for node negative breast carcinoma, and thus older age should not be a contraindication to axillary dissection.


Subject(s)
Arm/pathology , Breast Neoplasms/surgery , Edema/etiology , Lymph Node Excision/adverse effects , Mastectomy, Segmental/adverse effects , Postoperative Complications , Age Factors , Aged , Breast Neoplasms/pathology , Breast Neoplasms/radiotherapy , Female , Follow-Up Studies , Humans , Lymphatic Metastasis , Middle Aged , Risk Factors , Shoulder/pathology
20.
Int J Radiat Oncol Biol Phys ; 53(4): 862-7, 2002 Jul 15.
Article in English | MEDLINE | ID: mdl-12095551

ABSTRACT

PURPOSE: Factors affecting outcome in patients with surgicopathologic Stage II endometrial cancer are poorly defined. The purpose of this study was to determine prognostic factors in a series of patients treated according to standardized protocols at a single institution. METHODS AND MATERIALS: One hundred and seventy patients referred to Princess Margaret Hospital after hysterectomy between 1984 and 1995 were retrospectively reviewed. One hundred and twenty patients received postoperative external beam radiotherapy and brachytherapy, 18 received external beam radiotherapy alone, five received brachytherapy alone, and 27 had no radiotherapy. RESULTS: With a median follow-up of 5.1 years, overall and disease-free survival (DFS) at 5 years was 77% and 68%, respectively, and 24% of patients had relapsed. Significant independent adverse factors for DFS included age >65 (p = 0.0001), FIGO Stage IIB (p = 0.02), and capillary-lymphatic space (CLS) involvement (p = 0.0007). Prognostic factors for relapse were age (p = 0.0008), histologic grade (p = 0.01), and CLS (p = 0.01). A prognostic model based on the number of adverse prognostic factors (0-3) revealed that the 5-year survival rates for the four groups were as follows: 0%-85%, 1%-77%, 2%-55%, and 3%-11%. Combining the groups with 0 or 1 adverse factors resulted in a three-group variable that was strongly related to DFS (p < 0.0001). CONCLUSIONS: Patient age, stage, and CLS were significant factors for DFS, and age, grade, and CLS predicted time to relapse in Stage II endometrial cancer. A prognostic model for DFS using these factors can provide clinically meaningful outcome predictions.


Subject(s)
Carcinoma/diagnosis , Carcinoma/mortality , Endometrial Neoplasms/diagnosis , Endometrial Neoplasms/mortality , Adult , Aged , Aged, 80 and over , Brachytherapy , Disease-Free Survival , Female , Humans , Middle Aged , Prognosis , Regression Analysis , Risk Factors , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...